VivoSim Labs receives Nasdaq notice of stockholders' equity deficiency
VivoSim Labs received a notice on July 20, 2026, from Nasdaq's Listing Qualifications Staff that the company failed to meet the minimum $2,500,000 stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1), having reported stockholders' equity of $(1,099,000) in its Form 10-K for the period ended March 31, 2026. The company has 45 calendar days until September 3, 2026, to submit a compliance plan to Nasdaq, which may grant an extension of up to 180 calendar days until January 16, 2027, to regain compliance. The notice has no immediate effect on listing or trading; however, the company stated that as of the filing date, following a $5.0 million milestone payment from Eli Lilly, a $4.0 million private placement, and warrant exercises generating approximately $5.1 million in equity, stockholders' equity exceeded $2.5 million.
- Nasdaq notice received July 20, 2026, for failure to maintain minimum $2,500,000 stockholders' equity
- Company reported stockholders' equity of $(1,099,000) in Form 10-K for period ended March 31, 2026
- 45 calendar days from July 20, 2026 (until September 3, 2026) to submit compliance plan
- Nasdaq may grant extension of up to 180 calendar days from July 20, 2026 (until January 16, 2027)
- $5.0 million milestone payment from Eli Lilly upon achievement of development milestone
- Private placement closed July 17, 2026: pre-funded warrants and common warrants for gross proceeds of approximately $4.0 million
- Warrant exercises of 3,370,827 of 3,947,369 common stock warrants resulted in approximately $5.1 million increase to stockholders' equity
- As of filing date, stockholders' equity in excess of $2.5 million and 12,057,789 shares of common stock outstanding
VivoSim Labs faces a potential delisting if it cannot restore minimum stockholders' equity compliance within the cure period; however, recent transactions have temporarily brought the company above the threshold, making the compliance plan submission outcome the near-term determinant of continued Nasdaq listing.
- NT 10-K
- 8-Kthis filing
Derived from 8-K filed 2026-07-24. Not investment advice. Figures are extracted from the filing; prose is AI-assisted. View the source filing on SEC.gov →